← Back
aTYR PHARMA
ATYR · listed on Nasdaq · worth $12.35 million
$4.94
−3.82% on Oct 30
No insider bought aTYR PHARMA stock in the last year. They sold it 3 times, $6.3K in all.
No insider trades or company news in this range.
Reverse split 1-for-40 in Oct 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what ATYR ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
2.4M shares
98% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, three insiders sold aTYR PHARMA stock and none bought. None of the 3 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Sanjay Shukla, President and CEO.
Big investors
People and funds that reported owning 5% or more of aTYR PHARMA, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFederated Hermes5.1%Oct 7
All reports
Every insider trade and SEC report we hold for aTYR PHARMA.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 9, 2025BoughtPaul SchimmelOct 9, 2025 · Director+23%via a trust or family317,999 @ $0.9414$299.4K
Oct 9, 2025BoughtPaul SchimmelOct 9, 2025 · Traded Oct 8, 2025 · Director+62%via a trust or family682,001 @ $0.8980$612.4K
Analysts, earnings and news
Analysts' price target
$2.86 average
7 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26−$0.11 a share+$0.01
Q1 '26−$0.11 a share+$0.03
Q4 '25−$0.14 a share+$0.03
Q3 '25−$0.26 a share−$0.08